Abstract 769P
Background
Pharmacokinetic (PK) boosting is the intentional use of a drug-drug interaction to enhance systemic drug exposure. PK boosting of olaparib, a CYP3A-substrate, has the potential to reduce PK variability and financial expenses. The aim of this study was to investigate equivalence of a boosted, reduced dose of olaparib compared to the non-boosted standard dose.
Methods
This randomized, cross-over, multicenter trial compared the PK of olaparib 300 mg twice daily (BID) followed by olaparib 100 mg BID boosted with the non-therapeutic CYP3A-inhibitor cobicistat 150 mg BID for 7 days, or vice versa, in patients treated with olaparib. Equivalence was defined as a geometric mean ratio (GMR) of area-under-the-curve over one dosing interval (AUC0-12h) and 90% Confidence Interval (CI) within the no-effect boundaries of 0.57-1.25.
Results
Of 15 included patients, 12 were eligible for PK analysis. The AUC0-12h increased with the boosted reduced dose with a GMR of 1.45 (90% CI 1.27-1.65). The maximum plasma concentration was comparable (GMR 0.97; 90%CI 0.84-1.12), and the trough plasma concentration increased (GMR 4.14; 90%CI 3.25-5.27). PK parameters of both therapies are shown in the table. No grade ≥3 adverse events were reported during the study. Table: 769P
Pharmacokinetic parameters of the standard monotherapy and boosted therapy of olaparib. Data are represented as geometric mean (CV%) [confidence interval]
Monotherapy [95%CI] | Boosted therapy [95%CI] | Geometric mean ratio [90%CI] | |
AUC 0-12h (mg*h/L) | 29.4 (46%) [22.2 – 38.9] | 42.7 (41%) [33.2 – 55.1] | 1.45 [1.27 – 1.65] |
C max (mg/L) | 6.37 (37%) [5.07 – 8.00] | 6.19 (28%) [5.19 – 7.39] | 0.97 [0.84 – 1.12] |
T max (h) | 1.25 (66%) [0.85 - 1.83] | 1.67 (42%) [1.30 – 2.16] | 1.34 [1.03 – 1.75] |
C trough (mg/L) | 0.39 (107%) [0.21 – 0.73] | 1.56 (77%) [0.99 – 2.46) | 4.14 [3.25 – 5.27] |
Conclusions
Boosting a 100 mg olaparib dose with the strong CYP3A-inhibitor cobicistat increases olaparib exposure with 45%, compared to the standard dose of 300 mg. Boosting of olaparib is therefore a promising strategy to reduce the olaparib dose. These results encourage a prospective study of boosted olaparib with toxicity-guided dose reductions. If adequate tolerability is established, boosting can lead to a substantial reduction in olaparib therapy costs. Drs. N.A.D. Guchelaar and M.I. Mohmaed Ali have equally contributed to the study.
Clinical trial identification
NCT05078671.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
ZonMw , The Netherlands Organization for Health Research and Development, as part of the Goed Gebruik Geneesmiddelen program (grant 10140021910005).
Disclosure
R.H. Mathijssen: Financial Interests, Institutional, Research Grant, Investigator-initiated research: Astellas, Bayer, Cristal Therapeutics, Pfizer, Roche, Sanofi, Servier, Boehringer-Ingelheim, Novartis; Financial Interests, Institutional, Coordinating PI: Pamgene. I. Boere: Financial Interests, Institutional, Research Funding: GSK. P. Hamberg: Financial Interests, Personal, Advisory Board: Astellas, MSD, Pfizer, AstraZeneca, BMS, Ipsen. G.S. Sonke: Financial Interests, Research Funding: Merck, Agendia, AstraZeneca, Roche, Novartis; Financial Interests, Speaker, Consultant, Advisor: Novartis, Seattle Genetics, Biovica. N.P. Van Erp: Financial Interests, Institutional, Invited Speaker: Wad'n Workshop; Financial Interests, Institutional, Coordinating PI, IDS: Ipsen, Astellas. All other authors have declared no conflicts of interest.
Resources from the same session
628P - Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers
Presenter: Amos Stemmer
Session: Poster session 11
629P - First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
Presenter: David Tougeron
Session: Poster session 11
630P - Determining a prognostic score using imaging to assess the benefit of combo anti-PD1 + anti-CTL4 vs anti-PD1 in patients with metastatic MSI/dMMR colorectal cancer (mCRC MSI)
Presenter: Remy Barbe
Session: Poster session 11
631P - Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy
Presenter: Giulia Maddalena
Session: Poster session 11
632P - Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
Presenter: Sebastian Meltzer
Session: Poster session 11
633P - Genomic alterations in SPEN predict outcome of immune checkpoint therapy in gastrointestinal cancer
Presenter: Changxiong Wu
Session: Poster session 11
634P - The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers
Presenter: Michael Michael
Session: Poster session 11
635P - Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
Presenter: Marc van den Eynde
Session: Poster session 11